Abstract: Human PCAN1 (prostate cancer gene 1) is a prostate-specific gene that is highly expressed in prostate epithelial tissue, and frequently mutated in prostate tumors. To better understand the regulation of the PCAN1 gene, a 2.6-kb fragment of its 5' flanking region was obtained by PCR. Its promoter activity was examined via the dual-luciferase reporter assay after it had been cloned into a pGL 3 -basic vector generating pGL 3 -p2.6kb and transfected into LNCaP cells. pGL 3 -basic and pGL 3 -control were respectively used as the negative and positive controls. Sequence analysis with the MatInspector database showed that some possible binding sites for the transcriptional factors, NKX3.1, P53, SP1, cEBP and the PPAR/RXR heterodimers may locate on a 2.6-kb region upstream of the PCAN1 gene. To examine the relevant regulation of PCAN1, pGL 3 -p2.6kb was transfected into the prostate cancer cell line LNCaP, which was treated with R1881 (10 -7~1 0 -9 mol/l), 17β-estradiol (17β-E 2 , 10 -7~1 0 -9 mol/l), all-trans-retinoic acid (all-trans-RA, 10 -5~1 0 -7 mol/l) or 9-cis-retinoic acid (9-cis-RA, 10 -5~1 0 -7 mol/l), and eukaryotic expression plasmids of NKX3.1, p53, Sp1, Pten, PPARγ or cEBPα were cotransfected with pGL 3 -p2.6kb into LNCaP cells. pRL-TK, a Renilla luciferase reporter vector, was cotransfected into all the transfection lines as an internal control. The
INTRODUCTION
Prostate cancer is the most frequently diagnosed neoplasia in men and one of the leading causes of cancer-related deaths in men over 60 [1] . Once prostate cancer is identified in an individual, there is a limited number of treatment options. With no effective cure for the disease after it metastasizes and becomes androgen-independent [2, 3] , it is important to determine its biology. PCAN1 (prostate cancer gene 1, also known as GDEP) is highly expressed in the prostate epithelial tissue, and frequently mutated in prostate tumors [4] [5] [6] . It is localized to chromosome 4q21, a region of the genome that experiences frequent loss of heterozygosity (LOH) in prostate cancer. It is mutated in 35% of tumor samples. PCAN1 gene expression is localized to the prostate epithelial cells with the highest expression in the basal epithelial cells and lesser expression in the acinar epithelial cells [6] . This gradient of expression is lost in prostate tumors, where diffuse expression is observed throughout the tumor [6] . To elucidate the regulation of the PCAN1 gene, a 2.6-kb fragment of its 5' flanking region was amplified by PCR and cloned into the multiple clone sites of pGL 3 -basic, a promoter-less luciferase reporter vector, so that its promoter activity could be analyzed via the dual-luciferase report assay. This research will provide insight into the regulatory mechanism of PCAN1 expression in further studies.
MATERIALS AND METHODS
Amplification and subcloning of a 2.6-kb fragment of the 5' flanking region of the PCAN1 gene Human genomic DNA was extracted from white blood cells using the method of rapid isolation of mammalian DNA. The primer pair PF (5'-cccTAGCTAgccatctctgcagtctcgac-3'; with a Nhe I site at its 5' end) and PR (5'-cccAAGCTTcgctctgacttcctcttc-3'; with a Hind III site at its 5' end) were used to amplify the 5' flanking region of the PCAN1 gene from the extracted human genomic DNA. The PCR was conducted at 96ºC for 2 min followed by 32 cycles at 98ºC for 20 s, and 68ºC for 10 min. The PCR-amplified fragment was about 2.6 kb (+32 bp to -2598 bp), and it was subcloned into a T/A clone vector of pMD18-T (TaKaRa Biotech Co, Dalian China) to form a T/A cloning recombinant (pMD18-2.6 kb).
Construction of luciferase reporter plasmid
The 2.6 kb fragment was excised from pMD18-2.6 kb with Nhe I and Hind III (TaKaRa), and ligated into the equivalent site of the pGL 3 -basic vector (Promega, Madison WI, USA) to form the PCAN1 promoter-luciferase reporter constructs, designated pGL 3 -p2.6kb. The resulting construct was confirmed by restriction enzyme digestion and sequence analysis using the general primers Rvprimer3 and Rvprimer2.
Cell culture
LNCaP cells (ATCC -American Type Culture Collection) were grown at 37ºC in 5% CO 2 with RPMI 1640 (Gibco, BRL Gaithersburg, MD, USA) medium supplemented with 10% fetal bovine serum (FBS) (Gibco), 100 U/ml ampicillin and 100 U/ml streptomycin. Within 60 h of passage, LNCaP cells with more than 90% confluency were used for transfection.
Transient transfection
LNCap cells were transfected with lipofectimine TM 2000 (Promega) in 24-well plates. Each well contained 1.5 x 10 5 cells, 1.0 µg pGL 3 -p2.6kb, 0.04 µg of the internal control vector pRL-TK, 2 ml lipofectimine TM 2000, and 500 ml RPMI 1640 medium without serum or antibiotics, along with 0.5 µg of one of the eukaryotic expression plasmids pcDNA3.1-NKX3.1 (constructed in our lab), pCMV-p53 (Clonthch, Palo Alto, CA), pcDNA3.1-Sp1, pcDNA3.1-Pten (from Dr. Young, Mayo clinic, USA), pcDNA3.1-PPARγ, or pcDNA3.1-cEBPα (constructed in our lab). All the cells underwent the dual-luciferase reporter assay 48 h after the completion of the transfection procedure, following the protocol recommended by Promega.
Treatment of the transfected LNCaP cells
The stocks of R1881, 17β-E 2 , all-trans-RA and 9-cis-RA (Sigma, St.Louis, MO, USA) were prepared in ethanol. After the transfection of pGL 3 -p2.6kb in 24-well plates, the LNCaP cells were treated for 24 h with R1881 (10 -7~1 0 -9 mol/l in 2% charcoal treated FBS-RPMI 1640 media), 17β-E 2 (10 -7~1 0 -9 mol/l in 2% charcoal treated FBS-RPMI 1640 media), all-trans-RA (10 -5~1 0 -7 mol/l in 10% FBS-RPMI 1640 media), or 9-cis-RA (10 -5~1 0 -7 mol/l in 10% FBS-RPMI 1640 media). The controls received the ethanol vehicle at a concentration equal to that for the treated cells. All the cells underwent the dual-luciferase reporter assay 48 h after the completion of the transfection procedure.
Dual-luciferase reporter assay
The activities of firefly luciferase in pGL 3 and Renilla luciferase in pRL-TK (Promega) were determined following the dual-luciferase reporter assay protocol recommended by Promega. The cells were rinsed with PBS after harvest, and cell lysates were prepared by manually scraping the cells from the culture plates in the presence of 1 x PLB (passive lysis buffer). 20 µl of cell lysate was transferred into luminometer tubes containing 100 µ1 LAR. Firefly luciferase activity (M 1 ) was measured first, and then Renilla luciferase activity (M 2 ) was measured after the addition of 100 µl of Stop&Glo Reagent.
RESULTS
The construction and identification of the PCAN1 promoter-luciferase reporter plasmid (pGL 3 -p2.6kb) pGL 3 -p2.6kb was constructed with pGL 3 -basic and the 2.6-kb fragment that was excised from pMD18-2.6 kb with Nhe I and Hind III. The pGL 3 -p2.6kb construct was confirmed by restriction enzyme digestion ( Fig. 1 ) and DNA sequencing (Fig. 2) . Analyses of the 2.6-kb sequence using MatInspector 2.2 (http://www.gene-regulation.com) revealed potential binding sites for some important transcriptional factors within the 2.6-kb sequence, as shown in Fig. 2 . 
The transient transfection and promoter activity assay of pGL 3 -p2.6kb
The firefly luciferase expression driven by the 2.6-kb PCAN1 promoter was examined to evaluate its promoter activity. The transfections of the pGL 3 -control and pGL 3 -basic were respectively used as the positive and negative controls, and the pGL 3 -promoter containing a SV40 promoter was used for the comparison of promoter activity with the 2.6-kb PCAN1 promoter. The dual-luciferase reporter assay (M1/M2) yielded a result of 0.49 after 48 h of pGL 3 -p2.6kb transfection, which was about 60% of the pGL 3 activity. The M1/M2 of the transfections of pGL 3 -control and pGL 3 -basic were 1.7 and 0.05, respectively (Fig. 3) . Our results indicated that the cloned 2.6-kb fragment of the 5' flanking region of the PCAN1 gene represented promoter activity. Fig. 3 . The results of the promoter activity assay of pGL 3 -p2.6kb using the dualluciferase reporter assay in LNCaP cells. The 2.6-kb fragment of the 5' flanking region of the PCAN1 gene was inserted into the pGL 3 -basic vector to form pGL 3 -p2.6kb, which was contransfected with the pRL-TK plasmid (as an internal control) into LNCaP cells using lipofectimine 2000 TM . The promoter activities were determined via the dualluciferase reporter assay. The results are expressed as the relative luciferase activities (M1/M2), i.e. the ratio of firefly luciferase activity (M1) in the pGL 3 plasmid and Renilla luciferase activity (M2) in the pRL-TK plasmid. The data is the means of six individual values ± SD. The transfections of pGL 3 -control and pGL 3 -basic were used as the positive and negative controls, and the pGL 3 -promoter containing a SV40 promoter was used for the comparison of promoter activity. Fig. 4 . The effects of all-trans-RA and 9-cis-RA on the PCAN1 promoter activities of pGL 3 -p2.6kb in LNCaP cells. pGL 3 -p2.6kb was transfected into LNCaP cells treated with 10 -5~1 0 -7 mol/l all-trans-RA or 10 -5~1 0 -7 mol/l 9-cis-RA for 24 h. The effects of alltrans-RA and 9-cis-RA on the promoter activities were determined via the dualluciferase reporter assay. The results were expressed as relative luciferase activities (M1/M2). The data is the means of six individual values ± SD.
The effects of all-trans-RA and 9-cis-RA on PCAN1 promoter activities in LNCaP cells 24 h after the transfection of pGL 3 -p2.6kb, LNCaP cells were treated with alltrans-RA (10 -5~1 0 -7 mol/l) or 9-cis-RA (10 -5~1 0 -7 mol/l) for 24 h, and then harvested for the dual-luciferase report assay. The results showed that 9-cis-RA enhanced the PCAN1 promoter activity in a dose-dependent manner, while alltrans-RA had no significant effect on PCAN1 promoter activity (Fig. 4) .
The effects of R1881 and 17β-E 2 on PCNA1 promoter activities in LNCaP cells
LNCaP cells were cultured in RPMI 1640 media containing 2% charcoal-treated FBS and cotransfected with pGL 3 -p2.6kb and pRL-TK. 24 h after transfection, they were treated with R1881 (10 -7~1 0 -9 mol/l) or 17β-E 2 (10 -7~1 0 -9 mol/l) for 24 h. The results of the dual-luciferase report assay showed that treatment with R1881 and 17β-E 2 at different concentrations had no significant effect on PCAN1 promoter activities (Fig. 5) . The control cells were cotransfected with pGL 3 -p2.6kb and pcDNA3.1(+) plasmid. All the cells were analyzed for dual-luciferase reporter gene expression. The results in Fig. 6 show that NKX3.1, p53, Sp1 and Pten had positive regulation on PCAN1 promoter activities, with the respective PCAN1 promoter activities enhanced 1.66-, 2.48-, 2.00-and 1.72-fold compared with the PCAN1 promoter activity in the control. However, transfection with PPARγ and cEBPα expression plasmids had no significant effect on PCAN1 promoter activities. 
DISCUSSION
The PCAN1 gene is highly expressed in prostate epithelial tissue. It was initially identified in a screen for prostate-specific genes, the function of which may be important in prostate cancer initiation or progression [7] . This gene has been shown to be frequently mutated or deleted in prostate tumor samples [5] and in aberrantly regulated in tumor versus normal prostate tissue, indicating that PCAN1 has a tumor suppressor role in prostate cancer [6] . However, little is known about the regulatory mechanisms of PCAN1 gene expression or the relevant regulatory elements and factors. Our research on the PCAN1 gene was started to clone the promoter and to determine the factors which could affect its activity. In this study, 2.6 kb of the 5' flanking region of the PCAN1 gene was amplified by PCR using human genomic DNA as the template. To evaluate its promoter activity, the 2.6-kb fragment was cloned into the pGL 3 -basic vector, which contains a firefly luciferase reporter gene. Our results show that pGL 3 -p2.6kb provided a higher level of 1uciferase transcription in the LNCaP cell line than the promoter-less pGL 3 than the pGL 3 -promoter, which contained a putative strong promoter of SV40. This indicated that the cloned 2.6-kb of the 5' flanking region of the PCAN1 gene represented promoter activity. Analyses of the 2.6-kb sequence using MatInspector 2.2 on the Transfact Web site (http://www.gene-regulation.com) revealed potential binding sites for some important transcriptional factors (NKX3.1, P53, SP1, cEBP and PPAR/RXR heterodimers) implicated in prostate cancer. Furthermore, the analysis indicated the lack of a TATA-box within the presumed promoter region. However, we did not examine the role of downstream promoter elements in this study. Androgens are thought to be critical regulators of prostate differentiation and function, and of prostate cancer growth and survival [8] . They are involved in prostate cancer carcinogenesis and aggressiveness via the regulation of the expression of many genes [9] . To identify whether or not the PCAN1 gene is regulated by an androgen or estrogen in prostate cancer cells, we tested the effect of an androgen (R1881) and estrogen (17ß-E 2 ) on 2.6-kb promoter activity. Our results showed that R1881 and 17 ß-E 2 had no significant effect on PCAN1 promoter activity. The TRANSFAC software program showed that there are three progesterone response elements (GRE) within this 2.6-kb region of the PCAN1 gene, but no androgen response element (ARE) or estrogen response element (ERE) was found. Despite the presence of GREs, androgenic stimuli do not modulate the PCAN1 gene expression. Two nuclear receptor RXR binding sites were found within the 2.6-kb region, but no RAR. To examine the effect of retinoic acid on PCAN1 promoter activity, all-trans-RA and 9-cis-RA were used to treat the pGL 3 -p2.6kb-transfected LNCaP cells that express RAR and RXR [10] . Our results show that 9-cis-RA enhanced the PCAN1 promoter activity in a dose-dependent manner. 9-cis-RA is thought to be a differentiating agent and an inhibitor of carcinogenesis [11] [12] [13] [14] . It has demonstrated anti-proliferative and/or differentiating activity in in vitro models of prostate cancer [15] . Analyses of the 2.6-kb sequence using MatInspector 2.2 yielded more than 500 transcription factor binding sites (Matrix similarity > 0.75). We chose some transcription factors closely related to prostate cancer to test their effect on PCAN1 promoter activities. In our experiments, the eukaryotic expression plasmids of NKX3.1, p53, Sp1, Pten, PPARγ or cEBPα were cotransfected with pGL 3 -p2.6kb into LNCaP cells to test their regulatory effect on PCAN1 promoter activities. The results showed that PCAN1 promoter activities were upregulated by the expression of NKX3.1, p53 and Pten, which are thought to be important cancer suppressive genes in prostate carcinogenesis. NKX3.1 is a prostate-specific tumor suppressor. Loss of NKX3.1 expression correlates with the initiation of prostate carcinogenesis [16] and prostate tumor progression [17] . p53 and Pten are broad-spectrum tumor suppressors playing very important roles in various cancers including prostate cancer [18, 19] . Our findings that the PCAN1 gene, a highly expressed tumor suppressor, is regulated by p53 and Pten raised the possibility that the apparent tissue selectivity of broad-spectrum tumor suppressors may be generated through their regulation of tissue-specific genes to affect cell proliferation or differentiation as well as tumor progression. In summary, we cloned a 2.6-kb fragment of the 5' flanking region of the PCAN1 gene which represented promoter activity and was regulated by NKX3.1, p53, Sp1, Pten and 9-cis-RA in the luciferase reporter assay. Further research should be done to identify the functional cis-elements within the PCAN1 promoter and to study the specific regulatory mechanisms.
